Tyrosine kinase inhibitors exert their major antiangiogenic and antitumor effect in RCC by suppressing tyrosine kinase receptors on VEGFR and PDGFR and inhibiting their downstream signaling pathways. Here, KDR is linked to renal cell adenocarcinoma.